Level of Rural Development in Burdwan and Murshidabad Districts, West Bengal: A Comparative Study

The key purpose of this research is to examine the level of attainment of rural development in the two districts—Burdwan and Murshidabad. The reasons for selecting these two districts stems from the fact that majority of the population of these two districts dwell in rural areas. The concept of rural development is comprehensive. It includes economic development of rural people through the development of productive sectors and employment associated with rural infrastructural development as well human development. Therefore, rural development includes in its domain all the aspects of human development of the rural people. The present Central as well as State Governments have undertaken different policies and plans to bring about positive changes amidst the rural people. In most cases, however, the policies and plans fail to achieve the desired level of changes in the rural areas (Desai, 1991). Although in fewer isolated cases, some success has been achieved, but overall development remains to be reached. This research, based mainly on secondary data aims to investigate the scale of progress in the two districts —Burdwan and Murshidabad of West Bengal, India, in the areas embracing social correlates of rural poverty, basic infrastructure facilities, standard of living and quality of life. The data are analysed with the help of statistical and cartographical analysis

Socio-Economic Conditions and Quality of Life in the Tribal Areas of Orissa with Special Reference to Mayurbhanj District

Odisha (previously known as Orissa), being socio-economically backward but culturally sound, is one of the important states in Eastern India. Out of 30 districts 9 are considered as tribal districts (according to Location Quotient value) and of the total population (41,947,358 in 2011) a significant share (22.1%) goes to tribal people (8,145,081in 2011). This tribal group of Odisha has special significance because they are one of the most backward and geographically isolated communities. That’s why their life style and economy is confined to the direct utilization of natural resources, pre-agricultural level of technology and specific indigenous type of work. But now with the emergence of industry and market economy, the age-old relationship between tribes and nature has disturbed. Keeping this in backdrop, the present study tried to explore the changing scenario of socio-economic condition in the tribal areas of Odisha. In this regard, various socio-economic indicators have been analyzed and compared for representing district-level patterns of quality of life and finding out the variation among the Primitive tribal households in the study area. In addition, Mayurbhanj has also been taken as a case study to represent the socio-economic condition and quality of life at the block level. It may be pointed out in this context that out of 30 districts in Odisha, according to Location Quotient value Mayurbhanj is the highest tribal concentrated district. The overall objective of this study is to obtain a better understanding of disparities and variations in socio-economic status in Odisha as well as in Mayurbhanj and also find out some remedial measures to overcome the problems to bring the Primitive tribal community in the main stream of the society. Maps have been prepared on the above-mentioned indicators based on secondary data using Arc-GIS 9.3. From the analysis of the health-related indicators it is clear from the analysis that the quality of life in the district has improved remarkably over the years but socio-economic disparities in terms of caste and gender continue to be a major problem mostly in tribal and backward areas

Utilizing Reduced Graphene Oxide-Iron Nanoparticles Composite to Enhance and Accelerate the Removal of Methyl Blue Organic Dye in Wastewater

In this work, a nano-composite is used to remove dye from wastewater of different industries. For this purpose, thesynthesis of a magnetic 1:1 composite made of iron nanoparticles (NPs) using reduced graphene oxide is a novel techniqueand tested for Methyl Blue (MB) dye adsorption from aqueous solution. In this study Fe nanoparticles in reduced Graphenecomposite (FGOC) has been prepared using Graphene Oxide (GO). X-ray diffraction, FTIR spectroscopy and Ramanspectroscopy, are used to identify the structures. Many methods have been developed for MB removal in wastewater. One ofthe most popular methods is adsorption because it is simple and high-efficiency, and the adsorbent is crucial. It reached amaximum MB adsorption at pH 7. The kinetic study indicated that the adsorption of MB process was fitted well to thequasi-first-order and quasi-second-order kinetic models. The isotherm study revealed that the MB adsorption process obeyedthe Langmuir and Freundlich adsorption Isotherms models. The GO adding content and absorption conditions on the methylblue removal efficiencies were investigated. This adsorbent is easily recovered by an external magnetic field from thetreated wastewater and has high reusability

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017

A double burden of malnutrition occurs when individuals, household members or communities experience both undernutrition and overweight. Here, we show geospatial estimates of overweight and wasting prevalence among children under 5 years of age in 105 low- and middle-income countries (LMICs) from 2000 to 2017 and aggregate these to policy-relevant administrative units. Wasting decreased overall across LMICs between 2000 and 2017, from 8.4% (62.3 (55.1–70.8) million) to 6.4% (58.3 (47.6–70.7) million), but is predicted to remain above the World Health Organization’s Global Nutrition Target of <5% in over half of LMICs by 2025. Prevalence of overweight increased from 5.2% (30 (22.8–38.5) million) in 2000 to 6.0% (55.5 (44.8–67.9) million) children aged under 5 years in 2017. Areas most affected by double burden of malnutrition were located in Indonesia, Thailand, southeastern China, Botswana, Cameroon and central Nigeria. Our estimates provide a new perspective to researchers, policy makers and public health agencies in their efforts to address this global childhood syndemic

Production of He-4 and (4) in Pb-Pb collisions at root(NN)-N-S=2.76 TeV at the LHC

Results on the production of He-4 and (4) nuclei in Pb-Pb collisions at root(NN)-N-S = 2.76 TeV in the rapidity range vertical bar y vertical bar <1, using the ALICE detector, are presented in this paper. The rapidity densities corresponding to 0-10% central events are found to be dN/dy4(He) = (0.8 +/- 0.4 (stat) +/- 0.3 (syst)) x 10(-6) and dN/dy4 = (1.1 +/- 0.4 (stat) +/- 0.2 (syst)) x 10(-6), respectively. This is in agreement with the statistical thermal model expectation assuming the same chemical freeze-out temperature (T-chem = 156 MeV) as for light hadrons. The measured ratio of (4)/He-4 is 1.4 +/- 0.8 (stat) +/- 0.5 (syst). (C) 2018 Published by Elsevier B.V.Peer reviewe

Utilizing Reduced Graphene Oxide-Iron Nanoparticles Composite to Enhance and Accelerate the Removal of Methyl Blue Organic Dye in Wastewater

914-921In this work, a nano-composite is used to remove dye from wastewater of different industries. For this purpose, the synthesis of a magnetic 1:1 composite made of iron nanoparticles (NPs) using reduced graphene oxide is a novel technique and tested for Methyl Blue (MB) dye adsorption from aqueous solution. In this study Fe nanoparticles in reduced Graphene composite (FGOC) has been prepared using Graphene Oxide (GO). X-ray diffraction, FTIR spectroscopy and Raman spectroscopy, are used to identify the structures. Many methods have been developed for MB removal in wastewater. One of the most popular methods is adsorption because it is simple and high-efficiency, and the adsorbent is crucial. It reached a maximum MB adsorption at pH 7. The kinetic study indicated that the adsorption of MB process was fitted well to the quasi-first-order and quasi-second-order kinetic models. The isotherm study revealed that the MB adsorption process obeyed the Langmuir and Freundlich adsorption Isotherms models. The GO adding content and absorption conditions on the methyl blue removal efficiencies were investigated. This adsorbent is easily recovered by an external magnetic field from the treated wastewater and has high reusability

Pharmacology of epigenetics in brain disorders

Epigenetics is a rapidly growing field and holds great promise for a range of human diseases, including brain disorders such as Rett syndrome, anxiety and depressive disorders, schizophrenia, Alzheimer disease and Huntington disease. This review is concerned with the pharmacology of epigenetics to treat disorders of the epigenome whether induced developmentally or manifested/acquired later in life. In particular, we will focus on brain disorders and their treatment by drugs that modify the epigenome. While the use of DNA methyl transferase inhibitors and histone deacetylase inhibitors in in vitro and in vivo models have demonstrated improvements in disease-related deficits, clinical trials in humans have been less promising. We will address recent advances in our understanding of the complexity of the epigenome with its many molecular players, and discuss evidence for a compromised epigenome in the context of an ageing or diseased brain. We will also draw on examples of species differences that may exist between humans and model systems, emphasizing the need for more robust pre-clinical testing. Finally, we will discuss fundamental issues to be considered in study design when targeting the epigenome

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus.METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-analysis.RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (&lt;45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]).CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02065791